口服铁剂与视网膜/视网膜下出血相关:CATT试验事后分析
该研究为CATT试验的事后二次数据分析,纳入1165例新生血管性年龄相关性黄斑变性(AMD)患者,通过访谈了解口服铁剂使用情况,并由训练有素的阅片者评估基线眼底照相中的视网膜/视网膜下出血。结果显示,铁剂使用与基线出血相关(调整OR=1.47,P=0.04),且呈剂量依赖性(趋势P=0.048),在高血压患者中关联更显著(调整OR=1.87,P=0.006)。
要点
- 口服铁剂使用与新生血管性AMD患者视网膜/视网膜下出血相关,调整OR=1.47。
- 铁剂与出血的关联呈剂量依赖性,调整线性趋势P=0.048。
- 高血压患者中铁剂与出血关联更强,调整OR=1.87。
核心结论
- 在CATT试验参与者中,口服铁剂使用与视网膜/视网膜下出血呈剂量反应关系。
- 无适应症的铁剂补充可能对湿性AMD患者有害。
研究设计与样本
- CATT试验的事后二次数据分析,共纳入1165例新生血管性AMD患者。
- 通过访谈收集口服铁剂使用情况,由训练有素阅片者评估基线眼底照相中的视网膜/视网膜下出血。
- 采用多变量逻辑回归模型计算调整OR,调整年龄、性别、吸烟、高血压、贫血及抗血小板/抗凝药物使用。
主要发现
- 181例铁剂使用者中71%存在基线研究眼视网膜/视网膜下出血,984例未使用者中为61%(调整OR=1.47,P=0.04)。
- 铁剂使用与出血的关联呈剂量依赖性(调整线性趋势P=0.048)。
- 高血压患者中铁剂使用与出血相关(调整OR=1.87,P=0.006),非高血压患者中无此关联。
- 无贫血的高血压患者中铁剂使用与出血的关联仍显著(调整OR=1.85,P=0.02)。
临床怎么用
- 对湿性AMD患者应关注口服铁剂使用情况,避免无适应症补充铁剂。
- 高血压合并湿性AMD患者使用铁剂时需警惕视网膜/视网膜下出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Because patients often take iron supplements without medical indication, and iron can accumulate in vascular endothelial cells, the authors evaluated the association of oral iron supplementation with retinal/subretinal hemorrhage in patients with neovascular age-related macular degeneration. METHODS: A post hoc secondary data analysis of comparison of age-related macular degeneration treatments trials was performed. Participants were interviewed for use of oral iron supplements. Trained readers evaluated retinal/subretinal hemorrhage in baseline fundus photographs. Adjusted odds ratios from multivariate logistic regression models assessed the association between iron use and baseline hemorrhage adjusted by age, sex, smoking, hypertension, anemia, and use of antiplatelet/anticoagulant drugs. RESULTS: Among 1,165 participants, baseline retinal/subretinal hemorrhage was present in the study eye in 71% of 181 iron users and in 61% of 984 participants without iron use (adjusted odds ratio = 1.47, P = 0.04), and the association was dose dependent (adjusted linear trend P = 0.048). Iron use was associated with hemorrhage in participants with hypertension (adjusted odds ratio = 1.87, P = 0.006) but not without hypertension. The association of iron use with hemorrhage remained significant among hypertensive participants without anemia (adjusted odds ratio = 1.85, P = 0.02). CONCLUSION: Among participants of comparison of age-related macular degeneration treatments trials, the use of oral iron supplements was associated with retinal/subretinal hemorrhage in a dose-response manner. Unindicated iron supplementation may be detrimental in patients with wet age-related macular degeneration.
引用
- Song D, Ying GS, Dunaief JL, et al. ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. Retina. 2019. PMID: 30157115. doi:10.1097/IAE.0000000000002295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。